KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to -$400000.0.

  • Emergent BioSolutions' Gains from Investment Securities changed N/A to -$400000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $6.1 million, marking a year-over-year decrease of 317.46%. This contributed to the annual value of -$6.5 million for FY2024, which is 18024.69% down from last year.
  • Per Emergent BioSolutions' latest filing, its Gains from Investment Securities stood at -$400000.0 for Q3 2025.
  • Emergent BioSolutions' 5-year Gains from Investment Securities high stood at $18.9 million for Q4 2022, and its period low was -$2.6 million during Q4 2024.
  • In the last 5 years, Emergent BioSolutions' Gains from Investment Securities had a median value of $750000.0 in 2021 and averaged $3.0 million.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first skyrocketed by 620000.0% in 2022, then crashed by 230000.0% in 2025.
  • Emergent BioSolutions' Gains from Investment Securities (Quarter) stood at $300000.0 in 2021, then skyrocketed by 6200.0% to $18.9 million in 2022, then plummeted by 83.6% to $3.1 million in 2023, then crashed by 183.87% to -$2.6 million in 2024, then skyrocketed by 84.62% to -$400000.0 in 2025.
  • Its last three reported values are -$400000.0 in Q3 2025, -$2.2 million for Q2 2025, and $11.3 million during Q1 2025.